Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients
Authors:
- 1 October 2016
- journal article
- research article
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 73 (4) , 152-157
Abstract
Background and aims: miRNA-124 (miR-124) expression was known to be downregulated in patients with pancreatic ductal adenocarcinoma (PDAC). Downregulation of miR-124 was significantly associated with poor prognosis in patients with PDAC. Recent studies have shown that circulating miRNAs could be the potential biomarkers for invasive diagnostic as well as prognostic purposes. The purpose of the current study was to characterise the serum miR-124 levels and assess the clinical significance of serum miR-124 in patients with PDAC. Methods: Using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays, serum miR-124 levels were determined in serum from 126 patients with PDAC (53 resectable pancreatic cancer and 73 unresectable pancreatic cancer), 28 chronic pancreatitis patients and 47 healthy control individuals. The prognostic significance of miR-124 and other clinicopathological variables was determined using univariate and multivariate analyses. Results: Serum miR-124 levels were significantly decreased in patients with PDAC. Serum levels of miR-124 distinguished PDAC from chronic pancreatitis (P < 0.001) and healthy control subjects (P < 0.001). Low serum levels of miR-124 were significantly associated with lymph node metastasis, tumour node metastasis (TNM) stage and shorter survival time after surgery. In multivariate analysis, serum miR-124 (P = 0.001, HR: 2.47, 95% CI: 1.25–4.05), high TNM stage (P = 0.001, HR = 3.24, 95% CI: 2.03–8.08) and lymph node metastasis (P = 0.015, HR = 1.66, 95% CI: 1.02–3.13) were significant predictors. Conclusions: Serum miR-124 levels have utility as diagnostic biomarkers in patients with PDAC. These findings suggest, for the first time, that serum miR-124 levels may have prognostic impact in patients with PDAC.Keywords
This publication has 22 references indexed in Scilit:
- Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor PrognosisDigestive Diseases and Sciences, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real‐Time PCR AnalysisWorld Journal of Surgery, 2008
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences, 2008
- Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cellsNature Cell Biology, 2007
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2007
- MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinomaOncogene, 2007
- Expression profiling identifies microRNA signature in pancreatic cancerInternational Journal of Cancer, 2006
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006